U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H25N3O
Molecular Weight 263.3785
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LISDEXAMFETAMINE

SMILES

C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN

InChI

InChIKey=VOBHXZCDAVEXEY-JSGCOSHPSA-N
InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H25N3O
Molecular Weight 263.3785
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf | https://www.drugs.com/ppa/lisdexamfetamine.html | https://www.ncbi.nlm.nih.gov/pubmed/27125257

Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

2007
Primary
VYVANSE

Approved Use

VYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1)

Launch Date

2007
Primary
DEXEDRINE

Approved Use

Narcolepsy. Attention Deficit Disorder with Hyperactivity. As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.

Launch Date

1980
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
47.9 ng/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
24.7 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
36.6 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
60.7 ng × h/mL
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
431 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
70 mg 1 times / day multiple, oral
dose: 70 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LISDEXAMFETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.1 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXTROAMPHETAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Disc. AE: Irritability, Decreased appetite...
AEs leading to
discontinuation/dose reduction:
Irritability (1.3%)
Decreased appetite (0.86%)
Insomnia (0.86%)
Sources:
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Disc. AE: Delirium, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Delirium (acute)
Tachycardia
Hypertension
Tachypnea
Creatine kinase increased (mild)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Disc. AE: Insomnia, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Insomnia (2%)
Tachycardia (1%)
Irritability (1%)
Hypertension (1%)
Headache (1%)
Anxiety (1%)
Dyspnea (1%)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Disc. AE: Ventricular hypertrophy, Tic...
AEs leading to
discontinuation/dose reduction:
Ventricular hypertrophy (1%)
Tic (1%)
Vomiting (1%)
Psychomotor hyperactivity (1%)
Insomnia (1%)
Rash (1%)
Sources:
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Other AEs: Decreased appetite, Insomnia...
Other AEs:
Decreased appetite (below serious, 29 patients)
Insomnia (below serious, 7 patients)
Weight decreased (below serious, 3 patients)
Irritability (below serious, 6 patients)
Fatigue (below serious, 4 patients)
Nasopharyngitis (below serious, 2 patients)
Sources:
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Nausea...
Other AEs:
Nausea (below serious, 1 patient)
Sources:
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 4 patients)
Nausea (below serious, 1 patient)
Vomiting (below serious, 2 patients)
Sources:
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (below serious, 2 patients)
Nausea (below serious, 2 patients)
Sources:
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Diarrhea, Dry mouth...
Other AEs:
Diarrhea (below serious, 6 patients)
Dry mouth (below serious, 25 patients)
Fatigue (below serious, 6 patients)
Feeling jittery (below serious, 10 patients)
Irritability (below serious, 8 patients)
Upper respiratory tract infection (below serious, 5 patients)
Heart rate increased (below serious, 4 patients)
Weight decreased (below serious, 8 patients)
Anorexia (below serious, 4 patients)
Decreased appetite (below serious, 26 patients)
Headache (below serious, 20 patients)
Initial insomnia (below serious, 8 patients)
Insomnia (below serious, 10 patients)
Libido decreased (below serious, 4 patients)
Hyperhidrosis (below serious, 5 patients)
Sources:
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Abuse, Dependence...
AEs leading to
discontinuation/dose reduction:
Abuse
Dependence
Cardiovascular disorder (NOS) (grade 3-5)
Stroke (serious)
Myocardial infarction (serious)
Blood pressure increased
Heart rate increased
Psychiatric symptom NOS
Psychotic symptom
Manic symptom
Growth suppression
Vascular disorders
Raynaud's phenomenon
Serotonin syndrome
Sources:
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Decreased appetite, Dry mouth...
Other AEs:
Decreased appetite (below serious, 8 patients)
Dry mouth (below serious, 7 patients)
Insomnia (below serious, 10 patients)
Irritability (below serious, 3 patients)
Diaphoresis (below serious, 2 patients)
Libido decreased (below serious, 2 patients)
Tinnitus (below serious, 2 patients)
Muscle tension (below serious, 4 patients)
Tachycardia (below serious, 3 patients)
Paresthesia (below serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Decreased appetite 0.86%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Insomnia 0.86%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Irritability 1.3%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 13 - 17
Health Status: unhealthy
Age Group: 13 - 17
Sex: M+F
Sources:
Hypertension Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Tachycardia Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Tachypnea Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Delirium acute
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Creatine kinase increased mild
Disc. AE
1200 mg single, oral
Overdose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
healthy, 17
Health Status: healthy
Age Group: 17
Sex: F
Sources:
Anxiety 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Dyspnea 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Headache 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Hypertension 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Irritability 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Tachycardia 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Insomnia 2%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 18 - 55
Health Status: unhealthy
Age Group: 18 - 55
Sex: M+F
Sources:
Insomnia 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Psychomotor hyperactivity 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Rash 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Tic 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Ventricular hypertrophy 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Vomiting 1%
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy, 6 - 12
Health Status: unhealthy
Age Group: 6 - 12
Sex: M+F
Sources:
Nasopharyngitis below serious, 2 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Decreased appetite below serious, 29 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Weight decreased below serious, 3 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Fatigue below serious, 4 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Irritability below serious, 6 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Insomnia below serious, 7 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescents
Health Status: unhealthy
Age Group: adolescents
Sources:
Nausea below serious, 1 patient
20 mg single, oral
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Nausea below serious, 1 patient
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Vomiting below serious, 2 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Headache below serious, 4 patients
50 mg single, oral
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Headache below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Nausea below serious, 2 patients
70 mg single, oral
Dose: 70 mg
Route: oral
Route: single
Dose: 70 mg
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
Feeling jittery below serious, 10 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Insomnia below serious, 10 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Headache below serious, 20 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Dry mouth below serious, 25 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Decreased appetite below serious, 26 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Anorexia below serious, 4 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Heart rate increased below serious, 4 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Libido decreased below serious, 4 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Hyperhidrosis below serious, 5 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Upper respiratory tract infection below serious, 5 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhea below serious, 6 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Fatigue below serious, 6 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Initial insomnia below serious, 8 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Irritability below serious, 8 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Weight decreased below serious, 8 patients
70 mg 1 times / day steady, oral
Dose: 70 mg, 1 times / day
Route: oral
Route: steady
Dose: 70 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Abuse Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Blood pressure increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Dependence Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Growth suppression Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Heart rate increased Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Manic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Psychiatric symptom NOS Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Psychotic symptom Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Raynaud's phenomenon Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Serotonin syndrome Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Vascular disorders Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Cardiovascular disorder (NOS) grade 3-5
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Myocardial infarction serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Stroke serious
Disc. AE
70 mg 1 times / day multiple, oral
Recommended
Dose: 70 mg, 1 times / day
Route: oral
Route: multiple
Dose: 70 mg, 1 times / day
Sources:
unhealthy
Insomnia below serious, 10 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diaphoresis below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Libido decreased below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Paresthesia below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tinnitus below serious, 2 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Irritability below serious, 3 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tachycardia below serious, 3 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle tension below serious, 4 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry mouth below serious, 7 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Decreased appetite below serious, 8 patients
50 mg 1 times / day steady, oral
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely (co-administration study)
Comment: Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism; concomitant use of DEXEDRINE and CYP2D6 inhibitors may increase the exposure of DEXEDRINE;
Page: 4.0
no
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of systemic injections of dopaminergic agents on the habituation of rats submitted to an open field test.
2001
Determination of amphetamine in dog plasma by gas chromatography with mass selective detection.
2001 Apr
Tyrosine improves behavioral and neurochemical deficits caused by cold exposure.
2001 Feb
Differences in locomotor response to an inescapable novel environment predict sensitivity to aversive effects of amphetamine.
2001 Feb
Effects of acute D-amphetamine and ketamine on the performance of rats in a serial negative patterning procedure.
2001 Feb
The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered.
2001 Feb
Chronic inositol increases striatal D(2) receptors but does not modify dexamphetamine-induced motor behavior. Relevance to obsessive-compulsive disorder.
2001 Feb
Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse.
2001 Feb
The reverse transport of DA, what physiological significance?
2001 Feb
Highly sensitive analysis of methamphetamine and amphetamine in human whole blood using headspace solid-phase microextraction and gas chromatography-mass spectrometry.
2001 Feb 1
Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.
2001 Jan
Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task.
2001 Jan
Modification of d-amphetamine-induced responses by baclofen in rats.
2001 Jan
Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects.
2001 Jan
Behavioural and anti-psychotic effects of Ca2+ channel blockers in rhesus monkey.
2001 Jan 26
Differential effects of endomorphin-1 and -2 on amphetamine sensitization: neurochemical and behavioral aspects.
2001 Mar 1
Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes.
2008 Jan 8
Alopecia following initiation of lisdexamfetamine in a pediatric patient.
2009
Psychopharmacology of ADHD in pediatrics: current advances and issues.
2009
Case histories in pharmaceutical risk management.
2009 Dec 1
Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.
2009 Nov 15
Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.
2009 Oct
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
2010
Patents

Sample Use Guides

Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, DEXEDRINE may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. SPANSULE capsules may be used for once-a-day dosage wherever appropriate.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The action of several concentrations of d-amphetamine on the NADH-tetrazolium reductase histochemical reaction has been studied in several nervous regions of rats. The facts observed have demonstrated that d-amphetamine increases the intensity of the histochemical reaction by its action on NADH-oxido-reductase activity in all nervous regions studied.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:22:19 GMT 2025
Edited
by admin
on Mon Mar 31 18:22:19 GMT 2025
Record UNII
H645GUL8KJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
L-LYSINE-DEXTROAMPHETAMINE
Preferred Name English
LISDEXAMFETAMINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
Lisdexamfetamine [WHO-DD]
Common Name English
LISDEXAMPHETAMINE
Common Name English
lisdexamfetamine [INN]
Common Name English
Hexanamide, 2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl]-, (2S)-
Systematic Name English
N-[(1S)-1-Methyl-2-phenylethyl]-L-lysinamide
Systematic Name English
(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide
Systematic Name English
LISDEXAMFETAMINE [VANDF]
Common Name English
LISDEXAMFETAMINE [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175739
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
NCI_THESAURUS C29728
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
NDF-RT N0000175729
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
DEA NO. 1205
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
WHO-ATC N06BA12
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
WHO-VATC QN06BA12
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
LIVERTOX 562
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
Code System Code Type Description
PUBCHEM
11597698
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
DAILYMED
H645GUL8KJ
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
DRUG BANK
DB01255
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
NCI_THESAURUS
C75114
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
IUPHAR
7213
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
RXCUI
700810
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m6841
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY Merck Index
EVMPD
SUB32170
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
SMS_ID
100000124476
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
WIKIPEDIA
LISDEXAMFETAMINE
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
INN
8690
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
DRUG CENTRAL
4135
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
LACTMED
Lisdexamfetamine
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID00209652
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
CAS
608137-32-2
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201222
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
FDA UNII
H645GUL8KJ
Created by admin on Mon Mar 31 18:22:19 GMT 2025 , Edited by admin on Mon Mar 31 18:22:19 GMT 2025
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC